KIT inhibitor therapeutic - MetasTx
Latest Information Update: 04 Nov 2025
At a glance
- Originator MetasTx
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer